Fresenius Medical Care (NYSE:FMS) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research note issued to investors on Saturday. The firm set a “strong-buy” rating on the stock.

Separately, Truist Financial decreased their target price on Fresenius Medical Care from $24.00 to $22.00 and set a “hold” rating on the stock in a research note on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $22.00.

Fresenius Medical Care Stock Performance

NYSE:FMS opened at $21.09 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.09 and a current ratio of 1.46. Fresenius Medical Care has a 52-week low of $16.37 and a 52-week high of $23.29. The firm has a market cap of $12.38 billion, a price-to-earnings ratio of 23.70, a PEG ratio of 1.09 and a beta of 0.90. The business’s fifty day moving average is $19.45 and its 200 day moving average is $19.88.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.38. The company had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.28 billion. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. Research analysts predict that Fresenius Medical Care will post 1.51 EPS for the current year.

Hedge Funds Weigh In On Fresenius Medical Care

A number of institutional investors have recently added to or reduced their stakes in FMS. GAMMA Investing LLC boosted its holdings in shares of Fresenius Medical Care by 21.8% in the 1st quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock worth $82,000 after purchasing an additional 758 shares in the last quarter. Assetmark Inc. boosted its holdings in shares of Fresenius Medical Care by 169.9% in the 4th quarter. Assetmark Inc. now owns 4,178 shares of the company’s stock worth $87,000 after purchasing an additional 2,630 shares in the last quarter. ORG Partners LLC purchased a new position in shares of Fresenius Medical Care in the 1st quarter worth about $110,000. SageView Advisory Group LLC purchased a new position in shares of Fresenius Medical Care in the 1st quarter worth about $127,000. Finally, Signaturefd LLC boosted its holdings in shares of Fresenius Medical Care by 8.4% in the 2nd quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock worth $166,000 after purchasing an additional 672 shares in the last quarter. 8.25% of the stock is currently owned by institutional investors.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.